Lung Cancer | Specialty

FDA Grants Mobocertinib Breakthrough Designation for EGFR Exon 20–Mutant NSCLC

April 27th 2020

Mobocertinib (TAK-788) has received an FDA breakthrough therapy designation for the treatment of patients with EGFR exon 20-mutant non–small cell lung cancer.

Cemiplimab Improves Survival in Frontline PD-L1–High NSCLC

April 27th 2020

The PD-1 inhibitor cemiplimab significantly improved overall survival as a frontline treatment for patients with high–PD-L1 non–small cell lung cancer.

Sintilimab Plus Pemetrexed Frontline NSCLC Application Accepted in China

April 24th 2020

The National Medical Products Administration of China has accepted an application for the PD-1 inhibitor sintilimab injection for use in combination with pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer.

Tislelizumab Frontline Combo Takes Step Toward Chinese Approval in Squamous NSCLC

April 21st 2020

The China National Medical Products Administration has accepted a supplemental new drug application for the PD-1 inhibitor tislelizumab for use in combination with chemotherapy for the first-line treatment of patients with advanced squamous non–small cell lung cancer.

Nivolumab Plus Ipilimumab Improves Survival in Frontline Mesothelioma

April 20th 2020

Nivolumab combined with ipilimumab significantly improved overall survival versus chemotherapy in previously untreated patients with malignant pleural mesothelioma.

Managing Lung Cancer Patients Through the COVID-19 Crisis: What to Know

April 15th 2020

Join oncologists nationwide who have learned from the top leaders in the lung cancer field as they share their insights on coronavirus disease 2019 and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system. Join us Thursday, May 28, 2020 at 8 PM EST.

Tislelizumab Frontline Combo Improves PFS in Nonsquamous NSCLC

April 14th 2020

The PD-1 inhibitor tislelizumab combined with frontline chemotherapy significantly improved progression-free survival versus chemotherapy alone in patients with nonsquamous non–small cell lung cancer.

The Future of Lung Cancer Management

April 13th 2020

Limited-Stage SCLC: Is Immunotherapy an Option?

April 13th 2020

Small-Cell Lung Cancer: The IMpower133 and CASPIAN trials

April 13th 2020

Stage III NSCLC Progression Treatment Strategy

April 13th 2020

Stage III NSCLC: When to Start Durvalumab

April 13th 2020

Unresectable Stage III Lung Cancer Management

April 13th 2020

Brain Metastatic NSCLC: Targeted Therapy Approach

April 13th 2020

ALK-Rearranged & MET Exon 14 NSCLC Treatment Options

April 13th 2020

When to Re-Treat with Osimertinib

April 13th 2020

Oligometastatic and Small Cell Transformation Management

April 13th 2020

Upfront Targeted Treatment Approach

April 13th 2020

Lung Cancer Molecular Testing Protocol

April 13th 2020

When to Use the CheckMate-227 Regimen

April 13th 2020